Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oric Pharmaceuticals Inc (ORIC)

Oric Pharmaceuticals Inc (ORIC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 908,240
  • Shares Outstanding, K 100,358
  • Annual Sales, $ 0 K
  • Annual Income, $ -129,470 K
  • EBIT $ -143 M
  • EBITDA $ -144 M
  • 60-Month Beta 1.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.27

Options Overview Details

View History
  • Implied Volatility 149.14% (-65.19%)
  • Historical Volatility 180.07%
  • IV Percentile 47%
  • IV Rank 21.49%
  • IV High 436.15% on 02/05/26
  • IV Low 70.57% on 08/27/25
  • Expected Move (DTE 8) 0.93 (8.93%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 2,066
  • Volume Avg (30-Day) 410
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 6,201
  • Open Int (30-Day) 2,444
  • Expected Range 9.45 to 11.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 5
  • High Estimate $-0.28
  • Low Estimate $-0.35
  • Prior Year $-0.42
  • Growth Rate Est. (year over year) +26.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.23 +43.57%
on 04/02/26
13.04 -20.40%
on 03/31/26
-1.27 (-10.90%)
since 03/09/26
3-Month
7.23 +43.57%
on 04/02/26
14.25 -27.16%
on 02/25/26
+1.23 (+13.44%)
since 01/09/26
52-Week
4.19 +147.73%
on 04/10/25
14.93 -30.48%
on 10/07/25
+5.69 (+121.32%)
since 04/09/25

Most Recent Stories

More News
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 10.38 (+14.70%)
Stocks Settle Higher on Hopes for Conclusion to Iran War

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +0.72%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.18%. June E-mini...

ALK : 39.90 (-0.03%)
MPC : 223.52 (-3.65%)
SNDK : 851.57 (+9.05%)
HL : 19.30 (-1.23%)
CDE : 19.72 (unch)
LITE : 894.13 (-0.21%)
OXY : 58.53 (-2.07%)
NCNO : 17.69 (-0.28%)
GLW : 169.80 (+2.85%)
FANG : 186.31 (-0.09%)
STX : 500.77 (+0.90%)
WDC : 337.88 (-0.27%)
Stocks Climb on War-End Optimism

The S&P 500 Index ($SPX ) (SPY ) today is up +0.97%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.45%. June E-mini S&P futures (ESM26...

ALK : 39.90 (-0.03%)
MPC : 223.52 (-3.65%)
SNDK : 851.57 (+9.05%)
HL : 19.30 (-1.23%)
CDE : 19.72 (unch)
LITE : 894.13 (-0.21%)
OXY : 58.53 (-2.07%)
NCNO : 17.69 (-0.28%)
GLW : 169.80 (+2.85%)
FANG : 186.31 (-0.09%)
STX : 500.77 (+0.90%)
WDC : 337.88 (-0.27%)
Stocks Rally on Optimism that the War in Iran is Near a Conclusion

The S&P 500 Index ($SPX ) (SPY ) today is up +0.52%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.68%. June E-mini S&P futures (ESM26...

AMAT : 397.81 (+3.13%)
B : 42.43 (-0.19%)
SNDK : 851.57 (+9.05%)
HL : 19.30 (-1.23%)
CDE : 19.72 (unch)
$IUXX : 25,082.09 (+0.72%)
ASML : 1,448.64 (+1.94%)
ZNM26 : 111-075s (unch)
NCNO : 17.69 (-0.28%)
ESM26 : 6,863.25s (+0.58%)
STX : 500.77 (+0.90%)
WDC : 337.88 (-0.27%)
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026 ...

ORIC : 10.38 (+14.70%)
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 10.38 (+14.70%)
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 10.38 (+14.70%)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 10.38 (+14.70%)
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates

Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in...

ORIC : 10.38 (+14.70%)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 10.38 (+14.70%)

Business Summary

ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco,...

See More

Key Turning Points

3rd Resistance Point 9.74
2nd Resistance Point 9.48
1st Resistance Point 9.27
Last Price 10.38
1st Support Level 8.80
2nd Support Level 8.54
3rd Support Level 8.33

See More

52-Week High 14.93
Fibonacci 61.8% 10.83
Last Price 10.38
Fibonacci 50% 9.56
Fibonacci 38.2% 8.29
52-Week Low 4.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.